biostudies-literatureUnknown13(7)Khodarahmi MChronic low-grade inflammation is a probable mediator between the quantity of carbohydrate intake and health outcomes. The aim of this systematic review and meta-analysis of randomized clinical trials (RCTs) was to summarize the effects of low carbohydrate diets (LCDs) as compared to control diets on c-reactive protein (CRP) levels in adults. A comprehensive search was conducted in several databases up to February 2024. In total, 60 eligible trials with 5511 adults were included in the meta-analysis. LCDs resulted in an average reduction of 0.18 mg/L in CRP levels compared to control groups (MD = 0.18; 95% CI: 0.032 to 0.03; <i>p</i> = 0.016); however, sensitivity analysis revealed that this significance was dependent on a single study (Abbaspour Rad et al.), with exclusion of which the efFood science & nutritione70566https://www.ebi.ac.uk/biostudies/studies/S-EPMC12274166biostudies-literatureEffect of Low-Carbohydrate Diets on C-Reactive Protein Level in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.PMC12274166Khodarahmi MSeyedhosseini HAskari GfalseEffect of Low-Carbohydrate Diets on C-Reactive Protein Level in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Chronic low-grade inflammation is a probable mediator between the quantity of carbohydrate intake and health outcomes. The aim of this systematic review and meta-analysis of randomized clinical trials (RCTs) was to summarize the effects of low carbohydrate diets (LCDs) as compared to control diets on c-reactive protein (CRP) levels in adults. A comprehensive search was conducted in several databases up to February 2024. In total, 60 eligible trials with 5511 adults were included in the meta-analysis. LCDs resulted in an average reduction of 0.18 mg/L in CRP levels compared to control groups (MD = 0.18; 95% CI: 0.032 to 0.03; <i>p</i> = 0.016); however, sensitivity analysis revealed that this significance was dependent on a single study (Abbaspour Rad et al.), with exclusion of which the ef2025-01-01T00:00:00Z2025 Jul2026-03-18T14:16:29.848Z2025-08-23T03:08:54.522ZS-EPMC122741664068860310.1002/fsn3.70566